Mirna Therapeutics Company Profile (NASDAQ:SYBX)

About Mirna Therapeutics (NASDAQ:SYBX)

Mirna Therapeutics logoSynlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company's synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company's pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SYBX
  • CUSIP: N/A
  • Web: www.mirnarx.com
  • Market Cap: $275.5 million
  • Outstanding Shares: 16,282,000
Average Prices:
  • 50 Day Moving Avg: $17.00
  • 200 Day Moving Avg: $13.39
  • 52 Week Range: $7.84 - $23.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.98
  • P/E Growth: 0.00
  • Return on Equity: -44.70%
  • Return on Assets: -42.29%
  • Current Ratio: 33.87%
  • Quick Ratio: 33.87%
  • Average Volume: 16,852 shs.
  • Beta: 4

Frequently Asked Questions for Mirna Therapeutics (NASDAQ:SYBX)

What is Mirna Therapeutics' stock symbol?

Mirna Therapeutics trades on the NASDAQ under the ticker symbol "SYBX."

When did Mirna Therapeutics' stock split? How did Mirna Therapeutics' stock split work?

Mirna Therapeutics shares reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Mirna Therapeutics stock prior to the reverse split would have 14 shares after the split.

Where is Mirna Therapeutics' stock going? Where will Mirna Therapeutics' stock price be in 2017?

3 brokers have issued twelve-month price objectives for Mirna Therapeutics' stock. Their forecasts range from $14.00 to $25.00. On average, they expect Mirna Therapeutics' stock price to reach $19.50 in the next twelve months. View Analyst Ratings for Mirna Therapeutics.

Who are some of Mirna Therapeutics' key competitors?

Who are Mirna Therapeutics' key executives?

Mirna Therapeutics' management team includes the folowing people:

  • Michael F. Powell Ph.D., Chairman of the Board
  • Jose Carlos Gutierrez-Ramos Ph.D., President, Chief Executive Officer, Director
  • Todd Shegog, Chief Financial Officer, Secretary
  • Paul Miller, Chief Scientific Officer
  • Jay Stoudemire Ph.D., Vice President - Preclinical Development, Regulatory and Quality Assurance
  • Aoife M. Brennan, Chief Medical Officer
  • Casi DeYoung, Chief Business Officer
  • Edward T. Mathers, Independent Director

How do I buy Mirna Therapeutics stock?

Shares of Mirna Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirna Therapeutics' stock price today?

One share of Mirna Therapeutics stock can currently be purchased for approximately $16.47.

MarketBeat Community Rating for Mirna Therapeutics (NASDAQ SYBX)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Mirna Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mirna Therapeutics (NASDAQ:SYBX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $19.50 (18.40% upside)
Consensus Price Target History for Mirna Therapeutics (NASDAQ:SYBX)
Price Target History for Mirna Therapeutics (NASDAQ:SYBX)
Analysts' Ratings History for Mirna Therapeutics (NASDAQ:SYBX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017Leerink SwannInitiated CoverageOutperform -> Outperform$25.00LowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$14.00LowView Rating Details
11/15/2016HC WainwrightReiterated RatingHoldN/AView Rating Details
9/22/2016Citigroup Inc.Lower Price TargetNeutral$31.50 -> $14.00N/AView Rating Details
9/21/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Mirna Therapeutics (NASDAQ:SYBX)
No earnings announcements for this company have been tracked by MarketBeat.com


Earnings Estimates for Mirna Therapeutics (NASDAQ:SYBX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($0.50)($0.50)($0.50)
Q4 20171($0.50)($0.50)($0.50)
(Data provided by Zacks Investment Research)


Dividend History for Mirna Therapeutics (NASDAQ:SYBX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mirna Therapeutics (NASDAQ:SYBX)
Insider Ownership Percentage: 18.60%
Insider Trades by Quarter for Mirna Therapeutics (NASDAQ:SYBX)
Insider Trades by Quarter for Mirna Therapeutics (NASDAQ:SYBX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2016Jon IrvinVPSell280$1.43$400.40View SEC Filing  
11/1/2016Jon IrvinVPSell280$1.28$358.40View SEC Filing  
10/11/2016Jon IrvinVPSell150$1.83$274.50View SEC Filing  
10/3/2016Jon IrvinVPSell250$1.93$482.50View SEC Filing  
10/6/2015Michael PowellDirectorBuy857,142$7.00$5,999,994.00View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mirna Therapeutics (NASDAQ:SYBX)
Latest Headlines for Mirna Therapeutics (NASDAQ:SYBX)
finance.yahoo.com logoSynlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer
finance.yahoo.com - October 11 at 8:15 AM
americanbankingnews.com logoMirna Therapeutics (SYBX) and Its Competitors Financial Comparison
www.americanbankingnews.com - October 6 at 4:28 AM
americanbankingnews.com logoBiogen (BIIB) & Mirna Therapeutics (SYBX) Head to Head Contrast
www.americanbankingnews.com - September 29 at 10:02 AM
americanbankingnews.com logoFinancial Analysis: Mirna Therapeutics (SYBX) versus VIVUS (VVUS)
www.americanbankingnews.com - September 28 at 2:28 PM
americanbankingnews.com logoKamada (KMDA) and Mirna Therapeutics (SYBX) Head to Head Review
www.americanbankingnews.com - September 25 at 8:54 AM
americanbankingnews.com logoMirna Therapeutics (SYBX) versus Its Peers Head to Head Analysis
www.americanbankingnews.com - September 24 at 4:22 PM
americanbankingnews.com logoComparing Strongbridge Biopharma PLC (SBBP) & Mirna Therapeutics (SYBX)
www.americanbankingnews.com - September 23 at 12:40 PM
finance.yahoo.com logoSynlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 23 at 9:39 AM
americanbankingnews.com logoMirna Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($3.20) Per Share (SYBX)
www.americanbankingnews.com - September 21 at 8:42 AM
americanbankingnews.com logoLeerink Swann Comments on Mirna Therapeutics, Inc.'s Q3 2017 Earnings (SYBX)
www.americanbankingnews.com - September 20 at 6:36 AM
americanbankingnews.com logoMirna Therapeutics, Inc. (SYBX) Earns Outperform Rating from Analysts at Leerink Swann
www.americanbankingnews.com - September 19 at 8:58 AM
americanbankingnews.com logoMirna Therapeutics (SYBX) and Its Competitors Financial Analysis
www.americanbankingnews.com - September 17 at 10:16 AM
finance.yahoo.com logoSynlogic Presents New Preclinical Data at International Congress of Inborn Errors of Metabolism
finance.yahoo.com - September 7 at 9:38 AM
americanbankingnews.com logoMirna Therapeutics, Inc. (SYBX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 1 at 10:34 PM
finance.yahoo.com logoSynlogic to Webcast Presentation at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
finance.yahoo.com - September 1 at 9:24 AM



Mirna Therapeutics (SYBX) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.